Hisky Medical's CellTouch™ Confocal Micro-Optical Biopsy System: Real-Time, Non-Invasive Cellular Imaging for Early Cancer Detection

Early detection, early diagnosis, and early treatment are key strategies for reducing cancer mortality. When gastrointestinal cancers are detected at an early stage and managed with standardized therapy, the 5-year survival rate can exceed 95%. Endoscopy is one of the important tools for early cancer screening. However, many early-stage cancers present with subtle manifestations and are not easily detected during endoscopic examination.

Haiskell’s CellTouch™ is based on the imaging principles of laser scanning confocal microscopy, achieving high-resolution, cellular-level imaging in vivo. It enables endoscopists to observe real-time cellular images, facilitating non-invasive “optical biopsies” and immediate assessment of suspicious areas. Meanwhile, it provides targeted guidance for traditional pathological biopsies, improving biopsy accuracy while reducing tissue damage caused by the procedure. This represents a significant technology that helps increase the rate of early cancer intervention in China.

VCBeat Selects New Products Review, Issue 15, InvitesZuo Xiuli, Director of the Department of Digestive Endoscopy at Qilu Hospital of Shandong University; He Qiong, Chief Scientist at Hisky, presenting Haiscale's product introduction.

1. Superior Image Quality - High Resolution, High Contrast

Patented autofocus microscopic imaging technology achieves an excellent resolution of 1 μm per imaging point, accurately presenting the fine structures of tissues;

Patented Adaptive Dynamic Calibration Technology delivers high-contrast, high-sharpness images for clear delineation of tissue details.

2. Ultra-fast Imaging Speed – Motion-grade Imaging Speed

Patented high-speed scanning technology enables motion-grade high-speed imaging at up to 60 frames per second;

Maintains smooth, realistic visualization without trailing or stuttering during gastrointestinal peristalsis, perfectly rendering dynamic cellular structures.

3. Superior User Experience – Dual Display on a Single Screen

Supports synchronized display and automatic correlation of macroscopic tissue images and microscopic cellular images, with one-click switching between multiple display modes:

Real-time side-by-side comparison of target lesions and microscopic cells on a single screen eliminates the need for multi-screen observation, thereby enhancing detection efficiency.

Facilitates image-guided diagnosis and targeted biopsy, improves biopsy efficiency, reduces time spent on case retrieval for future reference and teaching purposes, and enhances overall work efficiency.

4. More Advanced Technology - Microvascular Imaging

Patented blood flow imaging technology for quantitative assessment of submucosal capillary distribution and hemodynamic information,

Quantitative assessment of local circulation aids in disease diagnosis, treatment evaluation, and assessment of tissue function.

Viewing Options: Scan the QR code on the poster below to add our assistant and reserve your spot for the live broadcast.

Zuǒ Xiùlì

Director, Department of Gastroenterology, Qilu Hospital of Shandong University

M.D., Chief Physician, Doctoral Supervisor. In July 2019, he was appointed as a Taishan Scholar Distinguished Professor of Shandong Province. He serves as Deputy Leader of the Functional Gastrointestinal Disorders Group of the Chinese Society of Gastroenterology, Vice Chairman of the Professional Committee on Digestive Endoscopy Molecular Imaging of the Chinese Research Hospital Association, Deputy Secretary-General of the Endoscopy Branch of the Chinese Medical Doctor Association, President-Elect of the Digestive Endoscopy Branch of the Shandong Medical Association, Vice Chairman of the Gastroenterology Branch of the Shandong Medical Association, and Vice Chairman of the Digestive Endoscopist Branch of the Shandong Medical Doctor Association.

As the principal investigator, I have led one key project under the National Key R&D Program “Intelligent Robots” during the 13th Five-Year Plan period of the Ministry of Science and Technology, one demonstration application study on the construction of a collaborative network for clinical medical research (digestive diseases) supported by the Ministry of Science and Technology, four General Programs of the National Natural Science Foundation of China, and two provincial-level natural science foundation projects. In addition, I have participated in multiple regional key and multicenter research projects. Throughout these endeavors, I have demonstrated strong capabilities in scientific research organization and technical problem-solving. Several projects have been successfully completed on schedule as planned, yielding substantial outcomes. To date, I have published more than 80 SCI-indexed papers, with an individual H-index exceeding 20, and my research findings have garnered widespread attention from peers.

He Qiong

Chief Scientist, Hisky

Graduated from the Department of Biomedical Engineering, School of Medicine, Tsinghua University; formerly a Postdoctoral Fellow and Associate Researcher at Tsinghua University. Has published over 80 academic papers and filed more than 300 patent applications. Recipient of funding from the National Key R&D Program, the National Natural Science Foundation of China (Young Scientists Fund), the China Postdoctoral Science Foundation (General Program), and the Postdoctoral Fellowship of the Tsinghua-Peking Center for Life Sciences. Honored with the China Association for Science and Technology’s Young Elite Scientists Sponsorship Program, the Chinese Medical Science and Technology Award, the Huang Jiasi Award from the Chinese Society of Biomedical Engineering, the Technical Invention Award from the China Society of Image and Graphics, and the Jiangsu Provincial Science and Technology Award, among others.

Wuxi Hisky Medical Technology Co., Ltd., spun out of Tsinghua University, is committed to the mission of “popularizing advanced technology and safeguarding public health.” The company is dedicated to providing innovative solutions for diseases affecting the liver, digestive system, breasts, and other areas. Hisky has developed multiple proprietary products, including the iLivTouch® non-invasive liver diagnostic system, the CellTouch™ confocal microscopic optical biopsy system, and the EQTouch™ high-end research ultrasound system. The company has participated in numerous national and provincial/ministerial-level science and technology projects, such as the National 12th Five-Year Plan Science and Technology Support Program and the National 13th Five-Year Plan Major Science and Technology Special Projects. To date, it has filed more than 500 patents domestically and internationally. Hisky has received numerous honors, including the First Prize of the Huaxia Medical Science and Technology Award, the Huang Jiasi Biomedical Engineering Award, the Second Prize of the Chinese Medical Science and Technology Award, the China Patent Excellence Award, and multiple provincial and municipal Science and Technology/Invention Awards. Currently, Hisky has obtained market certifications in the United States, the European Union, Japan, and other countries, with its products exported to nearly 50 countries and regions.

The independently developed CellTouch™ confocal microscopic optical biopsy system is built upon Hisky’s Ultimate-Micro ultra-micro technology platform, integrating confocal microscopy and fiber bundle imaging technologies. It magnifies live mucosal cells by 1,000 times, achieving micron-level resolution to enable cellular-level dynamic imaging and “optical biopsy” of human tissues. This product provides a novel tool for the non-invasive diagnosis of various clinical conditions, targeted biopsy, treatment monitoring, and surgical margin assessment, with applications spanning gastroenterology, pulmonology, surgery, and other fields. Hisky has reached an internationally advanced level in confocal imaging technology, and its products have been deployed at renowned hospitals across China, including Changhai Hospital Affiliated to Naval Medical University, Qilu Hospital of Shandong University, Dongfang Hospital Beijing University of Chinese Medicine, Renmin Hospital of Hubei Province, Beijing Tsinghua Changgung Hospital, Beijing Aerospace Central Hospital, Chongqing General Hospital, and Wuxi People’s Hospital.

“Artery Select New Product Launch” is a live-streaming series under “Artery Select” that supports medical enterprises in launching innovative products. The program’s mission is to empower the milestone launch of every innovative medical product.

Scan the QR code above to contact the assistant and schedule a live broadcast.

(If already added, please proactively contact the assistant)